Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis

Manmeet Ahluwalia, MD,1 Gene H. Barnett, MD,1 Di Deng, BS,2 Stephen B. Tatter, MD, PhD,3 Adrian W. Laxton, MD,3 Alireza M. Mohammadi, MD,1 Eric Leuthardt, MD,4 Roukoz Chamoun, MD,5 Kevin Judy, MD,6 Anthony Asher, MD,7 Marco Essig, MD, PhD,8 Jorg Dietrich, MD, PhD,9 and Veronica L. Chiang, MD2

1Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio; 2Department of Neurosurgery, Yale University, New Haven, Connecticut; 3Department of Neurosurgery, Wake Forest Medical Center, Winston-Salem, North Carolina; 4Department of Neurosurgery, Washington University, St. Louis, Missouri; 5Department of Neurosurgery, Kansas University, Kansas City, Kansas; 6Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania; 7Carolina Neurosurgery and Spine, Charlotte, North Carolina; 8Department of Radiology, University of Manitoba, Winnipeg, Manitoba, Canada; and 9Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

OBJECTIVE Laser Ablation After Stereotactic Radiosurgery (LAASR) is a multicenter prospective study of laser interstitial thermal (LITT) ablation in patients with radiographic progression after stereotactic radiosurgery for brain metastases.

METHODS Patients with a Karnofsky Performance Scale (KPS) score ≥ 60, an age > 18 years, and surgical eligibility were included in this study. The primary outcome was local progression-free survival (PFS) assessed using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria. Secondary outcomes were overall survival (OS), procedure safety, neurocognitive function, and quality of life.

RESULTS Forty-two patients—19 with biopsy-proven radiation necrosis, 20 with recurrent tumor, and 3 with no diagnosis—were enrolled. The median age was 60 years, 64% of the subjects were female, and the median baseline KPS score was 85. Mean lesion volume was 6.4 cm3 (range 0.4–38.6 cm3). There was no significant difference in length of stay between the recurrent tumor and radiation necrosis patients (median 2.3 vs 1.7 days, respectively). Progression-free survival and OS rates were 74% (20/27) and 72%, respectively, at 26 weeks. Thirty percent of subjects were able to stop or reduce steroid usage by 12 weeks after surgery. Median KPS score, quality of life, and neurocognitive results did not change significantly for either group over the duration of survival. Adverse events were also similar for the two groups, with no significant difference in the overall event rate. There was a 12-week PFS and OS advantage for the radiation necrosis patients compared with the recurrent tumor or tumor progression patients.

CONCLUSIONS In this study, in which enrolled patients had few alternative options for salvage treatment, LITT ablation stabilized the KPS score, preserved quality of life and cognition, had a steroid-sparing effect, and was performed safely in the majority of cases.

Clinical trial registration no.: NCT01651078 (clinicaltrials.gov)
https://thejns.org/doi/abs/10.3171/2017.11.JNS171273

KEYWORDS laser interstitial thermal therapy; NeuroBlate; metastatic brain tumor; radiation necrosis; Laser Ablation After Stereotactic Radiosurgery; LAASR; oncology

ABBREVIATIONS CNS = central nervous system; CR = complete response; FACT-Br = Functional Assessment of Cancer Therapy-Brain; HVLT-R = Hopkins Verbal Learning Test–Revised; KPS = Karnofsky Performance Scale; LAASR = Laser Ablation After Stereotactic Radiosurgery; LITT = laser interstitial thermal therapy; MMSE = Mini-Mental State Examination; OS = overall survival; PD = progressive disease; PFS = progression-free survival; PR = partial response; QOL = quality of life; RANO-BM = Response Assessment in Neuro-Oncology Brain Metastases; RN = radiation necrosis; SRS = stereotactic radiosurgery.


INCLUDE WHEN CITING Published online May 4, 2018,DOI: 10.3171/2017.11.JNS171273.
STEREOTACTIC radiosurgery (SRS) is the standard first-line treatment for most patients with a limited number of brain metastases. However, a portion of lesions treated with SRS will subsequently regrow, which can lead to neurological deterioration. This regrowth, seen on radiological follow-up, can be attributable to either true tumor recurrence/progression or an inflammatory nonneoplastic adverse effect of prior radiosurgery known as radiation necrosis (RN). Patients can be symptomatic from lesions in either scenario. Sneed et al. reported a 1-year local recurrence rate of 9.2% and a 1-year cumulative incidence rate of adverse radiation effects of up to 14%. Other studies have reported various rates of local recurrence ranging from 7% to 27.5% and rates of symptomatic radionecrosis ranging from 2% to 10%. Clinical outcome for patients with progressive brain metastasis or RN is generally poor and thought to be associated with a shortened lifespan and reduction in quality of life (QOL).

In patients with tumor regrowth, chemotherapy may improve survival but can significantly impact a patient’s QOL and should have no beneficial effect on RN. Medical treatments for RN can be expensive or have poorly tolerated adverse effects. Resection of both pathological entities has been shown to be beneficial in local control of the regrowing lesion if it is amenable to traditional craniotomy, but recovery from the craniotomy itself can take 4–8 weeks, which can be undesirable in a patient population with a limited lifespan. Further, patients undergoing repeat craniotomies are more likely to experience depression (20%) or systemic infection (4%) and to have a worse immediate postoperative neurological status (18%). In addition, repeat irradiation of lesions failing prior radiosurgery is associated with higher rates of RN.

Anecdotally, the option of MRI-guided laser interstitial thermal therapy (LITT) has been effective for the treatment of both pathological entities after SRS when craniotomy is not feasible because of either lesion location or concerns regarding medical comorbidities. Results from a phase I clinical trial using the NeuroBlate system (Monteris Medical Inc.) showed that the device provides neurosurgeons with a minimally invasive surgical option for tumor ablation. An earlier study in 16 glioblastoma patients suggested that LITT offers a survival advantage over medical management or chemotherapy alone.

Thus, the Laser Ablation After Stereotactic Radiosurgery (LAASR) study was designed to prospectively determine the safety, efficacy, and outcome of laser ablation for the treatment of recurrent brain metastases or RN following prior SRS.

Methods

Patients

This multisite, open-label phase II study of the FDA-cleared NeuroBlate system was performed across 6 centers in the United States with prior experience using laser ablation in the brain: 1) Cleveland Clinic, 2) Wake Forest University, 3) University of Kansas, 4) Washington University, 5) Thomas Jefferson University, and 6) Yale University. The study was registered with the ClinicalTrials.gov database (http://clinicaltrials.gov), and its registration no. is NCT01651078. Institutional review board approval was obtained at each site, and consent for the study was obtained per each site’s IRB requirements. Brain metastases patients with evidence of radiographic lesion growth following prior treatment with SRS were recruited into the study if they had a Karnofsky Performance Scale (KPS) score ≥ 60, an age > 18 years, and metastatic disease from a known primary cancer type and were good surgical candidates. Patients were excluded for any of the following reasons: 1) pregnancy; 2) leptomeningeal disease; 3) progressive symptoms due to mass effect despite steroids; 4) uncontrolled hypertension or cardiac dysrhythmia; 5) intracranial hemorrhage within the past 6 weeks; 6) serious concurrent systemic medical conditions; 7) concerns about coagulopathy including bone marrow suppression, thrombocytopenia, and the need for ongoing anticoagulation or antiplatelet therapy; and 8) an inability to undergo MRI because the scanner could not accommodate the patient’s physical dimensions or other reasons why MRI could not be performed. Nontarget lesions were allowed to be present on enrollment MRI as long as they were not expected (in the investigator’s judgment) to contribute to symptoms during the course of the study or to confound outcome interpretation.

Radiographic regrowth was defined by standard reports from a clinical radiologist at each institution. The decision to treat the radiological lesion with LITT was determined by a tumor board at each site. Factors used to decide to proceed with LITT included 1) the need for a diagnosis, 2) progression of symptoms (despite steroids) clearly attributable to a single lesion that would probably be ameliorated by resection, and 3) continued lesion growth over serial brain MRI sequences with a lesion size that was believed to be amenable to LITT based on individual center experience. Patient demographics, clinical cancer data, and all medical, radiation, and surgical treatment data were collected both prior and subsequent to LITT. The status of extracranial disease was defined by body imaging as reported at each institution. In addition, neurological functional data before and after LITT were collected.

Surgical Management

Preoperative gadolinium contrast-enhanced T1-weighted volumetric images were used for visualization, planning, and management. A biopsy was obtained in all cases to determine if lesion growth was attributable to tumor recurrence or RN. Pathology results of the biopsies were obtained from the pathology reports at each institution. All 6 centers used the NeuroBlate system for LITT, as previously described. The system employs a robotically controlled 1064-nm laser probe and uses MRI thermometry to inform the surgeon of predicted zones of protein denaturation and cell death.

Outcome Measures

The primary outcome was local central nervous system (CNS) progression-free survival (PFS) as defined by standard Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria. All pre- and postoperative images were independently reviewed by two neuroradiolog-
Statistical Analysis

Statistical analysis was performed using SAS software, version 9.1 (SAS Institute Inc.). The p values for discrete outcomes represent the probability of differences in the probability of an event over time using ANOVA and are presented as frequencies. The p values for continuous outcomes represent the probability of differences in mean outcomes over time using ANOVA and are presented as the median and interquartile range. The Kaplan-Meier method was used to obtain an estimate of OS. A multivariate analysis for discharge time was performed using logarithmic regression, and the following variables were included: confirmed biopsy, smoking status, heart disease, steroid use at baseline, and tumor volume. A p value < 0.05 was considered to indicate statistical significance.

Results

Overall Demographics and Procedure

Forty-four patients were screened into the LAASR study between October 2012 and December 2015, but only 42 patients were treated with LITT because 2 patients did not fulfill study entry criteria. Mean age of the patients was 58.5 years (range 32–74 years), and 27 (64.3%) of the 42 patients were female. The primary tumor pathology was non–small cell lung cancer in 43% of patients, breast cancer in 17%, melanoma in 10%, and other tumor types in 30% (Table 1). Median baseline KPS score was 85 (range 60–100), and 43% of patients (18/42) were on steroids at study entry. Twelve patients (28.6%) had previously undergone craniotomy for tumor resection, and 7 patients (16.7%) had received previous whole-brain radiation therapy. Only 1 patient was receiving ongoing chemotherapy prior to LITT.

Mean lesion volume was 6.4 cm³ (range 0.4–38.6 cm³). Tumor was in the frontal lobe in 41% of cases, parietal lobe in 29%, cerebellum in 14%, and other in 16% (occipital lobe, temporal lobe, thalamus, and other deep nuclei). Pathological analysis of the biopsy at the time of LITT showed recurrent tumor in 20 cases (48%), RN without evidence of tumor in 19 cases (45%), and was nondiagnostic in 3 cases (7%). Median procedure time was 3 hours (range 1.4–9.7 hours), and median length of hospital stay was 2 days (range 0.4–12 days).

After LITT, of the 20 patients with a biopsy diagnosis of recurrent tumor, postoperative chemotherapy/medical therapy information was available for only 5, who received ongoing treatment with ipilimumab + nivolumab (1), dabrafenib (1), trastuzumab (1), pemetrexed (1), and lapatinib (1).

In comparing patients with recurrent brain metastases to those with RN, we found no statistically significant differences in age, sex, race, medical comorbidities, primary cancer type, baseline KPS score, percentage using steroids at baseline, prior local treatment, tumor location, or tumor volume (Table 1). Median length of stay was 2.3 days (range 1–12 days) for tumor patients and 1.7 days (0.5–6.5 days) for RN patients (p = 0.11).

Outcome

Twenty-seven patients (64%) completed the 12-week follow-up, and 16 patients (38%) completed the full 26-week follow-up (Fig. 1). Therefore, imaging, cognition, and QOL outcomes as well as complication data were only available for some of the patients (Table 2), although OS data are available for all patients.

Local PFS

Local PFS for the group with available data was 74% (20/27) at 12 weeks and through the last follow-up (12–26 weeks). At 12 weeks, 15% (4/27) of the LITT-treated lesions were stable, 22% (6/27) had a partial response (PR), and 37% (10/27) had a complete response (CR). Ultimately, 48% (13/27) of LITT-treated lesions for which follow-up was available showed a CR. At both the 12- and 26-week time points, 26% of the lesions continued to progress despite LITT treatment (Table 2).

Additional analysis of local PFS at 12 weeks was performed based on whether the lesion was totally or subtotally ablated. Ablation data were only available for 9 RN lesions and 12 tumor regrowth lesions. Of the lesions that had received total ablation, 100% (4/4) of the RN lesions and 75% (3/4) of the tumor lesions showed a CR (Table 2). The remaining 25% (1/4) of tumors that were totally ablated showed a PR. These findings contrast with those for the tumors that had received subtotal ablation: 0% showed a CR and 63% (5/8) showed progressive disease (PD). In total, 7 (87.5%) of 8 lesions that were totally ablated demonstrated radiographic CR compared with 0 (0%) of 13 lesions that were subtotally ablated. Achieving a radiographic CR was shown to be statistically significantly related to having received total ablation (p < 0.001). In addition, of the lesions demonstrating PD at 12 weeks, all had been confirmed as tumor tissue on biopsy and had undergone incomplete ablation at the time of LITT treatment.

Comparing the two groups based on pathology, we found local PFS was statistically different at 12 weeks (100% for RN vs 54% for tumor, p = 0.016) but not at the last follow-up beyond 12 weeks (91% for RN vs 62% for tumor, p = 0.166; Table 3). The local PFS increase in the tumor group at the last follow-up compared with 12 weeks was attributable to a single tumor case that was categorized as PD at 12 weeks according to the RANO-BM criteria but subsequently became a CR at the 26-week evaluation after radiation treatment for progression. This patient also received trastuzumab during follow-up. The tumor patient recorded as receiving the ipilimumab + nivolumab combination had a radiographic CR at both the 12- and 26-week follow-ups.
Only 8/42 (19%) patients experienced local lesional progression during the course of the study, and the majority of these patients had biopsy-confirmed metastatic tumor. Patients who went on to have progressive lesions did have a lower baseline KPS score than those without progressive lesions (median 70 vs 90, p = 0.0037); however, there were no other significant differences in baseline characteristics. Patients who did have radiographic local lesion progression were more likely to be moved to hospice or to die during the course of the study (HR 0.12, p = 0.027) after the 12-week follow-up.

Overall Survival and Neurological Outcome

Overall survival for the whole group was 86.5% at 12 weeks and 72.2% at 26 weeks. For tumor patients, OS was 71% at 12 weeks and 64.5% at 26 weeks. For RN patients, OS survival was 100% at 12 weeks and 82.1% at 26 weeks. Overall survival was significantly different between the two groups at 12 weeks (p = 0.02) but not at 26 weeks (p = 0.09; Fig. 2).

The median change in the KPS score was 0 (range −40 to +20), and 60% (25/42) of the patients had stable or improved KPS at their last visit, and 31% were able to stop or reduce steroid usage by the 12-week follow-up. No statistically significant difference in these percentages for either neurological change or change in

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Regrowing Tumor Group</th>
<th>Radiation Necrosis Group</th>
<th>p Value*</th>
<th>All Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>20</td>
<td>19</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>70.0%</td>
<td>63.2%</td>
<td>0.7411</td>
<td>64.3%</td>
</tr>
<tr>
<td>Male</td>
<td>30.0%</td>
<td>36.8%</td>
<td></td>
<td>35.7%</td>
</tr>
<tr>
<td>Age in yrs</td>
<td></td>
<td></td>
<td>0.9980</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>58.9 ± 11.2</td>
<td>58.8 ± 7.5</td>
<td></td>
<td>58.5 ± 9.9</td>
</tr>
<tr>
<td>Median (range)</td>
<td>60.0 (32.0–74.0)</td>
<td>58.0 (49.0–72.0)</td>
<td></td>
<td>60.0 (32.0–74.0)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White†</td>
<td>85.0%</td>
<td>89.5%</td>
<td>0.6050</td>
<td>88.1%</td>
</tr>
<tr>
<td>Asian</td>
<td>0%</td>
<td>5.3%</td>
<td></td>
<td>2.4%</td>
</tr>
<tr>
<td>African American</td>
<td>15.0%</td>
<td>5.3%</td>
<td></td>
<td>9.5%</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>30.0%</td>
<td>10.5%</td>
<td>0.3466</td>
<td>19.0%</td>
</tr>
<tr>
<td>Never</td>
<td>25.0%</td>
<td>36.8%</td>
<td></td>
<td>31.0%</td>
</tr>
<tr>
<td>Quit &gt;6 mos ago</td>
<td>45.0%</td>
<td>52.6%</td>
<td></td>
<td>50.0%</td>
</tr>
<tr>
<td>History of heart disease</td>
<td></td>
<td></td>
<td>1.0000</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>30.0%</td>
<td>26.3%</td>
<td></td>
<td>26.2%</td>
</tr>
<tr>
<td>Never</td>
<td>65.0%</td>
<td>73.7%</td>
<td></td>
<td>68.0%</td>
</tr>
<tr>
<td>Prior</td>
<td>5.0%</td>
<td>0%</td>
<td></td>
<td>4.8%</td>
</tr>
<tr>
<td>Primary tumor site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>10.0%</td>
<td>26.3%</td>
<td>0.6883</td>
<td>16.7%</td>
</tr>
<tr>
<td>GYN</td>
<td>0%</td>
<td>0%</td>
<td></td>
<td>2.4%</td>
</tr>
<tr>
<td>NSCLC</td>
<td>50.0%</td>
<td>36.8%</td>
<td></td>
<td>42.9%</td>
</tr>
<tr>
<td>SCLC</td>
<td>5.0%</td>
<td>5.3%</td>
<td></td>
<td>4.8%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>10.0%</td>
<td>10.5%</td>
<td></td>
<td>9.5%</td>
</tr>
<tr>
<td>Other</td>
<td>25.0%</td>
<td>15.8%</td>
<td></td>
<td>21.4%</td>
</tr>
<tr>
<td>Renal</td>
<td>0%</td>
<td>5.3%</td>
<td></td>
<td>2.4%</td>
</tr>
<tr>
<td>Baseline KPS score</td>
<td></td>
<td></td>
<td>0.1986</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>79.5 ± 11.9</td>
<td>84.7 ± 13.1</td>
<td></td>
<td>82.1 ± 13.0</td>
</tr>
<tr>
<td>Median (range)</td>
<td>80.0 (60.0–100.0)</td>
<td>90.0 (60.0–100.0)</td>
<td></td>
<td>85.0 (60.0–100.0)</td>
</tr>
<tr>
<td>Steroid use at baseline</td>
<td>40.0%</td>
<td>36.8%</td>
<td>1.0000</td>
<td>42.9%</td>
</tr>
<tr>
<td>No. of lesions</td>
<td>23</td>
<td>19</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Mean lesion vol in cm³ (range)</td>
<td>7.1 ± 8.7 (0.8–38.6)</td>
<td>5.5 ± 3.9 (0.4–13.2)</td>
<td>0.4185</td>
<td>6.4 ± 6.7 (0.4–38.6)</td>
</tr>
</tbody>
</table>

GYN = gynecological; NSCLC = non–small cell lung cancer; SCLC = small cell lung cancer.

Data expressed as mean ± standard deviation, median (range), or %.

* The value calculated from the 2-sample t-test for continuous summary and Fisher’s exact test for categorical summary.

† 100% non-Hispanic ethnicity.
steroid use after LITT were seen between the tumor and RN groups. Figure 3 shows FLAIR and gadolinium MRI examples taken pre-LITT and at 26 weeks after LITT.

Cognition and QOL
No significant change was noted in the HVLT-R or MMSE scores between baseline and the 12- or 26-week results for the overall group. In addition, no significant change was noted in the overall FACT-Br scores at either time point; however, when the scale was divided into its subcategories, a statistically significant decline in Social Well-Being (SWB) scores was seen at 12 weeks (median -1.0, range -12 to 8.2, p = 0.0443) and in Emotional Well-Being (EWB) scores at 26 weeks (median 3.5, range -5 to 11, p = 0.0170). This decline in EWB and SWB scores was seen in both tumor and RN patients, and the lack of a correlation between disease progression and worsened QOL was confirmed using interaction plots for correlations. However, increased FACT-Br scores (indicative of worsening QOL) were significantly associated with a greater likelihood of death or being moved to hospice (HR = 0.972, p = 0.044). In addition, there was no significant effect of prior whole-brain radiation therapy on cognition or QOL.

Complications
Overall, 35 of 42 patients developed adverse events during the study. Adverse events were defined as any undesirable medical occurrence in a clinical trial patient, regardless of whether it was related to the device or not, that included a clinical sign, symptom, or condition and/or an observed unintended technical performance or performance outcome of the device. No unanticipated adverse device events occurred during the study. Five patients (12%) incurred an immediate LITT-related neurological complication (Table 4). In 4 of these cases, LITT had been performed adjacent to motor, sensory, and/or speech areas, and postoperatively these patients had new or worsened neurological deficits. In the fifth case, an intracerebral hemorrhage occurred but did not result in the need for craniotomy or a new neurological deficit.

During the subsequent postoperative admission, 14 patients (33%) had surgery-related adverse events. The most common adverse events were transient neurological symptoms and seizures (7), nausea/vomiting (3), cardiopulmonary events (3), and an asymptomatic increase in radio-

### TABLE 2. RANO-BM outcomes by time point and ablation coverage

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Complete Response</th>
<th>Partial Response</th>
<th>Stable Disease</th>
<th>Progressive Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>12-wk local lesion response (n = 27)</td>
<td>37% (10/27)</td>
<td>22% (6/27)</td>
<td>15% (4/27)</td>
<td>26% (7/27)</td>
</tr>
<tr>
<td>12-wk response</td>
<td>74% PFS</td>
<td>26% progression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last FU* local lesion response (n = 27)</td>
<td>48% (13/27)</td>
<td>15% (4/27)</td>
<td>11% (3/27)</td>
<td>26% (7/27)</td>
</tr>
<tr>
<td>Last FU* response</td>
<td>74% PFS</td>
<td>26% progression</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 12-wk local lesion progression by pathology & ablative coverage |
|------------------|------------------|------------------|
| RN, total ablation (n = 4) | 100% (4/4) | 0 | 0 | 0 |
| RN, subtotal ablation (n = 5) | 0 | 60% (3/5) | 40% (2/5) | 0 |
| Tumor, total ablation (n = 4) | 75% (3/4) | 25% (1/4) | 0 | 0 |
| Tumor, subtotal ablation (n = 8) | 0 | 12.5% (1/8) | 25% (2/8) | 62.5% (5/8) |

* Anytime from 12 to 26 weeks: 16/42 (38%) patients submitted follow-up imaging at 26 weeks, and 27 total patients submitted imaging for analysis.
graphically defined cerebral edema (3). Twenty-two of 42 patients had adverse events recorded beyond 1 month after surgery—due to progression of disease in 10—and only 1 patient was readmitted within 90 days for pulmonary embolism.

There was no significant difference in the rate of overall adverse events between the tumor group and RN group (p = 0.69).

Discussion

Patients who develop radiographic lesion recurrence or progression after SRS treatment for brain metastasis can benefit from surgical management, especially if the cause of the radiographic regrowth is RN. In patients who cannot or are unwilling to undergo craniotomy, LITT can be performed as an alternative to craniotomy and has been anecdotally reported to be efficacious in managing this problem.

The first report of LITT use in this patient population appeared in 2008, in which Carpentier et al. described the feasibility and safety of LITT treatment for regrowing metastases in 4 patients. While only 3 of the 4 patients had...
Together, the data suggest that it is important to biopsy le-

cions showing radiological evidence of growth at the time

810

of LITT to guide the discussion of the need for additional post-LITT treatment.

This study also demonstrated that successful LITT can result in stabilization of the KPS score, preservation of
cognition and QOL, and reduction in the use of steroids. While there is limited literature with which to compare
our findings, one can interpret our results as an improve-
ment in outcome compared with the expected progressive

dence in function of this patient population due to con-
tinued lesion growth.

Neurological complications related to LITT were seen
in 12% of patients. It is known that LITT adjacent to the
subcortical motor sensory fibers can cause permanent neu-
rological deficits. A recent publication by Sharma et al.14
showed that overlap between the area of LITT and the
corticospinal tracts, as defined by diffusion tensor imaging
fiber tracking, can result in a permanent deficit. Patients
with lesions close to the corticospinal tracts may benefit
from functional imaging studies (for example, tractogra-
phy) prior to LITT to guide intraoperative treatment.

This study, while prospective, is limited by its small
sample size, lack of a matched cohort treated using either
craniumotomy or best medical therapy, and high study drop-

<table>
<thead>
<tr>
<th>TABLE 4. Adverse events associated with LITT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Events</td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
<tr>
<td>No. of patients</td>
</tr>
<tr>
<td>% total patients w/ events</td>
</tr>
<tr>
<td>Complete hemiparesis (%)</td>
</tr>
<tr>
<td>Headache (%)</td>
</tr>
<tr>
<td>Hemineglect and Lt.-sided weakness (%)</td>
</tr>
<tr>
<td>Immediate postop effects (%)</td>
</tr>
<tr>
<td>Intracerebral hemorrhage (%)</td>
</tr>
<tr>
<td>Weakness (%)</td>
</tr>
</tbody>
</table>

Adverse event relatedness was based on event adjudication. Adverse events are site reported.
* Immediately postoperatively, the patient presented with left upper-extremity weakness, slight left facial droop, full body itchiness, and persistent dyspraxia (outcome: recovering/resolving).

Complete lesional treatment, all had improvement in their KPS score 3 months after surgery. Since then, several oth-
er investigators have detailed their experience (single cases or case series) and have described variable success with
LITT for the treatment of both biopsy-proven regrowing tumors8,10,20 and biopsy-proven RN.4,11,16

Therefore, the current study was performed to prospectively determine the safety, efficacy, and outcome of LITT
for regrowing SRS-treated lesions. Our results confirm that LITT can be effective in controlling both recurrent/pro-
gressive brain metastases and RN following SRS. Overall survival for the whole group was 86.5% at 12 weeks and
72.2% at 26 weeks. Survival at 12 weeks was significantly better in the patients with biopsy-proven RN than in those
whose biopsy showed recurrent tumor, although there was no statistical significance by 26 weeks after LITT—prob-
ably due to the sharp fall-off in patients remaining in the study beyond 12 weeks.

In cases in which LITT was successful in this study, radiographic control or resolution of the concerning lesion
was demonstrated in all but 1 case by 12 weeks. Radi-
ographic CR was more likely to occur if total ablation of
the lesion had been achieved (p < 0.001), and local PFS
was significantly better for biopsy-proven RN lesions
(100% at 12 weeks) than for biopsy-proven tumor (54%
at 12 weeks; p = 0.016). While a median PFS duration of
37 weeks was previously reported by Rao et al.,12 these
authors had not performed biopsies; therefore, the differ-
ential proportion of progressive brain metastases or RN in
that study remains unknown. Smith et al.16 reported a me-
dian PFS of 11.4 months in a group of patients treated with
LITT for biopsy-proven RN, a result not inconsistent with
the findings in our study. In addition, Ali et al.1 showed
that in patients with biopsy-proven recurrent tumor, post-
LITT treatment with hypofractionated radiation resulted
in 100% lesion control compared with only 57% control if
additional radiation was not administered following LITT.
Together, the data suggest that it is important to biopsy le-
sions showing radiological evidence of growth at the time

Conclusions

In summary, this prospective study confirmed that
LITT is a low-risk surgical procedure that can control ra-
diographic lesion (either tumor or RN) growth after SRS
in patients with brain metastases and should be considered
in those who are surgically eligible. Additional benefits
may include minimizing cognitive decline, stabilizing
QOL and functional status, and allowing the cessation of
steroids in some patients. Further studies with a control
group for better characterization of possible benefits are
 warranted. Biopsy at the time of LITT is recommended
to guide follow-up care decisions. For patients with RN,
LITT is a good treatment option. Regardless of whether
a lesion was totally or subtotally ablated, LITT resulted
in close to 100% lesion control and > 80% survival at 6
months. In patients with recurrent tumor, however, while
LITT can achieve local control if the lesion is totally ablat-
ed, the rate of local control in our study was far lower than
for RN; therefore, additional therapeutic intervention such
as further local radiation or systemic therapies should be
considered postoperatively. Larger studies with longer follow-up and comparison with the natural history of lesions in untreated patients are needed to elucidate which factors may best predict improved outcomes after LITT and the timing of consolidative therapy. The difficulty with which patients may accrue to such a study, however, may need to be factored into the design of future studies.

Acknowledgments

We thank Nissa Mollema, PhD, of Monteris Medical for her careful review of this manuscript and editorial assistance.

References


Disclosures

Monteris Medical Corporation sponsored this study. Drs. Ahluwalia, Chiang, Dietrich, Laxton, Leuthardt, and Mohammadi are consultants for Monteris Medical Corporation. Dr. Barnett is a consultant for and owns stock in Monteris Medical Corporation.

Author Contributions

Conception and design: Chiang, Ahluwalia, Barnett, Tatter, Laxon, Mohammadi, Leuthardt, Chamoun, Judy, Asher, Essig, Dietrich. Acquisition of data: Chiang, Ahluwalia, Barnett, Tatter, Laxon, Mohammadi, Leuthardt, Chamoun, Judy, Asher. Analysis and interpretation of data: Chiang, Deng. Drafting the article: Chiang, Deng. Critically revising the article: Chiang, Ahluwalia, Barnett, Deng, Laxon, Mohammadi, Leuthardt, Chamoun, Judy, Asher, Essig, Dietrich. Approved the final version of the manuscript on behalf of all authors: Chiang. Study supervision: Chiang, Ahluwalia, Barnett, Tatter, Laxon, Mohammadi, Leuthardt, Chamoun, Judy, Asher, Essig, Dietrich.

Supplemental Information

Previous Presentations

A portion of this material was previously presented at the Society of NeuroOncology Annual Meeting in Scottsdale, Arizona, on November 18, 2016.

Correspondence

Veronica L. Chiang: Yale University, New Haven, CT. veronica.chiang@yale.edu.